The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R 1 is -Q 1 -A 1 and the like； ---- is a double bond or a single bond； when ---- is a double bond, W 1 is a nitrogen atom or a group represented by the general formula: =C(R a )-, and W 2 is a nitrogen atom or a group represented by the general formula: =C(R b ) -； when ---- is a single bond, W 1 is a group represented by the general formula: -C(R aa )(R ab )- or a group represented by the general formula: -(C=O) -, and W 2 is a group represented by the general formula: C(R ba )(R bb )-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(R bc )-； W 3 , W 4 and W 5 are each independently a nitrogen atom or a methine group and the like that may have a substituent； X is a single bond, an oxygen atom and the like； Y is a single bond or (CR Yi R Yi' ) n ； and Z is a hydroxyl group or COOR 2 and the like.
